Login to Your Account



Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's

By Marie Powers
Staff Writer

Friday, January 25, 2013
newco_news_resized.jpg

Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications – spinal cord injury (SCI) and Alzheimer's disease (AD) – that have bedeviled biotechs and big pharmas, alike.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription